Table 3 Medical treatment and outcome of treatment between patients with CMV-positive and CMV-negative Posner-Schlossman syndrome

 Number of patients treated with antiglaucoma medication

20 (90.9)

15 (60)

.015*

 Number of antiglaucoma agents used simultaneously

2.0 (1.5–2.4)

1.0 (0.6–1.5)

.005*

 Frequency of corticosteroid eye drop (times per day)

2.5 (2.1–2.9)

2.8 (2.5–3.1)

.271

 Number of patients with corticosteroid dependency

13 (59.1)

12 (48)

.447

 IOP (mm Hg)

16.7 (15.0–18.3)

14.4 (13.2–15.7)

.016*

 IOP reduction (mm Hg) (compared with the IOP at the first clinic visit)

13.0 (7.8–18.1)

14.6 (10.4–18.8)

.129

 mutton-fat KPs

9 (40.9)

15 (60)

.191

 Coin-shaped KPs

1 (4.5)

0 (0)

.281

 Tyndall effect

0 (0)

0 (0)

NA

 Number of patients treated with antiglaucoma medication

11 (50)

8 (32)

.210

 Number of antiglaucoma agents used simultaneously

1.0 (0.5–1.5)

0.5 (0.2–0.9)

.148

 Frequency of corticosteroid eye drop (times per day)

0.5 (0.2–0.9)

1.0 (0.5–1.4)

.213

Duration of follow-up (weeks)

4.9 (3.8–6.0)

5.9 (4.7–7.2)

.202